Negative hyper-selection using ctDNA gene alterations, such as KRAS, NRAS, BRAFV600E, PTEN, EGFR, HER2, MET, and gene fusions, may help identify patients who would benefit from panitumumab over bevacizumab regardless of primary tumor sidedness, suggesting its potential usefulness as a biomarker for anti-EGFR therapy resistance [112]. The gene discussed is EGFR; the disease is neoplasm.